ResMed stock (US7611521078): ex-dividend date approaches on May 14

ResMed Inc, a leader in sleep and respiratory care devices, approaches its ex-dividend date on May 14, 2026. Shareholders of record on that date will receive a quarterly cash dividend of $0.60 per share, payable on June 18, 2026, according to Moomoo as of May 12, 2026. This follows a prior quarterly dividend declaration of $0.53 per share payable June 12, 2025, per Simply Wall St. The stock recently traded at $203.79 on May 13, 2026, according to IndMoney data.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

ResMed Inc: core business model

ResMed Inc develops, manufactures, and distributes medical devices and cloud-based software for sleep apnea, respiratory care, and related conditions. The company operates in two main segments: Sleep and Respiratory Care, and Software as a Service (SaaS). Its products include CPAP machines, masks, and digital health platforms like myAir, which track patient compliance. ResMed holds a significant share in the global sleep apnea market, with strong US exposure via its NYSE listing.

The business model emphasizes recurring revenue from consumables like masks and filters, alongside device sales. This dual approach provides stability, as replacement parts drive about half of sales. ResMed's innovation in connected devices appeals to US healthcare providers focused on telehealth and chronic disease management.

Main revenue and product drivers for ResMed Inc

Sleep apnea devices remain ResMed's primary revenue driver, accounting for the majority of sales in the Sleep and Respiratory Care segment. Key products include the AirSense and AirCurve series, which integrate cloud connectivity for remote monitoring. Earnings grew 15.7% over the past year ending in fiscal 2025, per Simply Wall St.

SaaS solutions, including Brightree and MatrixCare, contribute growing revenue from outpatient and post-acute care software. These platforms serve US providers, enhancing ResMed's relevance for American investors tracking digital health trends. Consumables and accessories provide high-margin, recurring income.

Industry trends and competitive position

The sleep apnea market benefits from rising awareness of untreated sleep disorders' health risks, driving US demand. ResMed competes with Philips Respironics but leads in market share and innovation, particularly in auto-adjusting CPAP tech. Regulatory approvals for new masks bolster its pipeline.

Digital health integration positions ResMed well amid US telehealth expansion post-pandemic. Challenges include supply chain issues for components, but the company's scale supports resilience.

Why ResMed Inc matters for US investors

Listed on the NYSE, ResMed offers US investors direct access to a defensive healthcare play with exposure to aging demographics and obesity trends. Its SaaS segment taps into the booming US digital health market, projected to grow significantly. Dividend payouts provide yield amid volatility.

Conclusion

ResMed Inc continues to deliver steady dividends and innovation in sleep care, with the upcoming ex-dividend date drawing investor attention. Its US-centric revenue and NYSE listing make it relevant for American portfolios focused on healthcare stability. Market dynamics around chronic care trends warrant monitoring, alongside upcoming earnings on July 31, 2025.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.